Eli Lilly and Company

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: LLY-1 Category:

Description

Eli Lilly & Company: Product pipeline evolution with focus on improved patient outcomes! 

 

Eli Lilly and Company’s Q4 2023 earnings showed a year of growth and advancement for the company. Revenue increased by 20 percent for the full year and 28 percent for the most recent quarter, as seen in the company’s newly launched portfolio gaining momentum. Notably, the company received regulatory approvals for Zepbound, Jaypirca, Omvoh, Ebglyss in the EU, and an expanded label for Verzenio and two new indications for Jardiance within 2023. Such advances demonstrate Eli Lilly’s potential to drive robust revenue growth and margin expansion over time.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!